DENZA Partners with DEVIALET on Car Audio System
23.3.2023 20:00:00 EET | Business Wire | Press release
On 22nd March 2023, the DENZA x DEVIALET Cooperation Kick-off Evening was held at the Bay Opera of Shenzhen. DENZA and DEVIALET jointly unveiled the DENZA N7, the world's first mass-produced model coming with the DEVIALET car audio system. This cooperation witnesses DENZA become the first brand to apply DEVIALET’s audio system and serves as a paradigm of international cooperation in the global automotive industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005522/en/
DENZA x DEVIALET Cooperation Kick-off Evening (Photo: Business Wire)
Zhao Changjiang, General Manager of DENZA, said: “High-quality music brings users enjoyment of life, and intelligent music cockpit is the standard element for the new luxury.”
Franck Lebouchard, CEO of DEVIALET, commented, “This is a collaboration between two market leaders with a mission to redefine sound experiences in mobility. Our partnership with DENZA marks a partnership concluded with a future leading player in the automotive market.”
Making the journey sound better, DENZA N7 comes with a new acoustic system that offers Hi-Fi sounds with cutting-edge technology and creates an intelligent music cockpit offering an immersive and pleasant sound experience. The tailor-made speaker in DENZA N7 can create an expansive yet precise sound field while preserving Hi-Fi precision. The SAM® (Speaker Active Matching) technology is employed to produce ultra-low frequencies down to 20Hz, creating a more powerful bass performance. The DEVIALET SPACE technology is used to deliver stereo sound effects and create an immersive ambiance. The SDVC (Speed Dependent Volume Control) technology unique to DEVIALET provides automatic volume adjustment depending on the speed of the vehicle.
DENZA N7 is where auto-design aesthetics meets with the art of acoustics. It features a look that inherits the DENZA family’s new design language, π-Motion. The golden ratio of 0.618 and the design of the long wheelbase combined with short front and rear suspensions render an elegant yet sporty body. The “Meteor Arrow” symbol running through the body presents a sharp-cut vibrant mark that is easy to identify. The front of N7 looks like a “bullet” pointing forward, creating a feeling of high speed. The waistlines are the perfect embodiment of the π-Motion design language as well. Fluent and graceful, the curved surface is seemingly poised to rein the wind. The one-piece through taillight strip extends to both sides, making it look as wide as a shooting brake. Zhao Changjiang said: “As a unique all-electric shooting brake, DENZA N7 brings perceived value that outstrips oil-fueled luxury SUVs and takes the exterior design of electric SUVs to the next level.”
Amid a new wave of internationalization, DENZA will align with more premium brands across multiple sectors, enrich the aesthetic meaning of luxury life, and bring an intelligent, accessible, and comfortable mobility experience to global users.
HD Photos: https://we.tl/t-nxUJMK6LWT
About DENZA
In 2010, Mercedes-Benz, as the "inventor of automobile", and BYD Auto, as the "leader of new energy vehicles", established DENZA, China's first joint venture brand of new energy vehicles with a high-end brand position to realize their common vision of the future of electric mobility by complementing each other's strengths. DENZA combines BYD's world-leading power batteries, electric motors, electronic control systems with Mercedes-Benz's intelligent manufacturing capability, vehicle tuning, and quality management systems.
About DEVIALET
DEVIALET is a French acoustical engineering company operating at the intersection of luxury and cutting-edge technology. DEVIALET’s mission is to elevate sound to its rightful place in people's lives by delivering uniquely meaningful audio experiences through iconic products.
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005522/en/
Contact information
Asia-Pacific: Mia Gu, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com tel: +56 9 96443906
Brazil: Adalberto Maluf, adalberto.maluf@byd.com tel: +19 3514 2554
Middle East and Africa: Nikki Li, tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom